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Modeling the Transition From Decompensated to Pathological
Hypertrophy
Florencia Pascual, PhD; Jonathan C. Schisler, PhD; Trisha J. Grevengoed, PhD; Monte S. Willis, MD, PhD; Rosalind A. Coleman, MD
Background-—Long-chain acyl-CoA synthetases (ACSL) catalyze the conversion of long-chain fatty acids to fatty acyl-CoAs.
Cardiac-specific ACSL1 temporal knockout at 2 months results in a shift from FA oxidation toward glycolysis that promotes
mTORC1-mediated ventricular hypertrophy. We used unbiased metabolomics and gene expression analyses to examine the early
effects of genetic inactivation of fatty acid oxidation on cardiac metabolism, hypertrophy development, and function.
Methods and Results-—Global cardiac transcriptional analysis revealed differential expression of genes involved in cardiac
metabolism, fibrosis, and hypertrophy development in Acsl1H/ hearts 2 weeks after Acsl1 ablation. Comparison of the 2- and
10-week transcriptional responses uncovered 137 genes whose expression was uniquely changed upon knockdown of cardiac
ACSL1, including the distinct upregulation of fibrosis genes, a phenomenon not observed after complete ACSL1 knockout.
Metabolomic analysis identified metabolites altered in hearts displaying partially reduced ACSL activity, and rapamycin treatment
normalized the cardiac metabolomic fingerprint.
Conclusions-—Short-term cardiac-specific ACSL1 inactivation resulted in metabolic and transcriptional derangements distinct from
those observed upon complete ACSL1 knockout, suggesting heart-specific mTOR (mechanistic target of rapamycin) signaling that
occurs during the early stages of substrate switching. The hypertrophy observed with partial Acsl1 ablation occurs in the context of
normal cardiac function and is reminiscent of a physiological process, making this a useful model to study the transition from
physiological to pathological hypertrophy. ( J Am Heart Assoc. 2018;7:e008293. DOI: 10.1161/JAHA.117.008293.)
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M itochondrial oxidation of long-chain fatty acids (FAs)accounts for 60% to 90% of the energy used by the
adult heart under normal physiological conditions, with
glucose and lactate oxidation providing the remainder.1–4
The healthy heart is metabolically flexible and can readily
switch between energy substrates as dictated by substrate
availability, hormonal status, and physiological environment.5
Pathological conditions can also be accompanied by alter-
ations in cardiac substrate use; however, it remains unclear as
to whether the shift in energy substrate is a cause or
consequence of the pathological insult. Metabolic heart disease
causes an increase in FA oxidation,6–9 whereas increased
glucose use is observed under conditions that induce patho-
logical hypertrophy, myocardial ischemia, or heart failure.10
Analyses of some mouse models suggest that ventricular
hypertrophy precedes the metabolic changes that result in
reduced cardiac FA oxidation and increased glucose use.11,12
Conversely, studies of ex vivo working hearts have shown that
hemodynamic stress is sufficient to elicit mechanistic target of
rapamycin complex-1 (mTORC1)-responsive increases in glu-
cose use and cardiac remodeling, whereas perfusing working
hearts with glucose results in mTORC1-mediated hypertrophy
and contractile dysfunction,13 compelling indicators that
reliance on glucose may be detrimental to cardiac function.
Murine cardiac acyl-CoA synthetase (ACSL) 1 deficiency
results in decreased mitochondrial FA oxidation and suggests
that a shift to glycolysis promotes the progressive develop-
ment of mTORC1-mediated hypertrophy and diastolic dys-
function.14,15 The activation of FA via the formation of
acyl-CoA derivatives is required for their downstream utiliza-
tion as energy substrates or complex lipid precursors. ACSL1
belongs to a family of 5 closely related ACSL isoforms and is
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highly expressed in oxidative tissues like brown adipose
tissue, skeletal muscle, and heart, where it directs FA
preferentially toward mitochondrial b-oxidation.14,16,17 Hearts
lacking ACSL1 exhibit a >90% reduction in mitochondrial FA
oxidation and a 35% decrease in the uptake of the nonme-
tabolizable FA analog 2-bromo-[1-14C]-palmitate. In contrast,
the uptake of non-metabolizable 2-deoxy[1-14C]-glucose
increases 8-fold, and pyruvate oxidation and tricarboxylic
acid cycle flux also increase significantly, suggesting that
ACSL1-deficient hearts must rely almost exclusively on
glucose for energy.15 These metabolic changes are accom-
panied by a marked increase in mTORC1 activation and the
development of mTORC1-mediated pathological hypertrophy,
diastolic dysfunction, and increases in oxidative stress,
suggesting that a forced substrate switch toward glucose
oxidation is not entirely benign.15,18
While cardiac hypertrophy is generally considered to be
an initial, compensatory response to increased cardiac
workload, chronic ventricular hypertrophy typically precedes
the onset of heart failure, and the transition from physio-
logical to maladaptive hypertrophy is still poorly understood.
Previous studies have shown that cardiac function is not
affected by partial ablation of Acsl1.14 Thus, the present
work was designed to examine the molecular mechanisms
that underlie the development of cardiac hypertrophy in the
context of preserved cardiac function during the early
stages of cardiac ACSL1 depletion and the resulting
inhibition of FA use. We hypothesized that this incomplete
ablation model would allow us to study the changes in
cardiac metabolism that precede morphologic or functional
changes; such changes would shed light on the role of
glucose metabolism in mediating these processes. Thus, we
asked whether partial Acsl1 knockdown would result in
transcriptional and metabolic changes similar to those
observed in ACSL1-deficient hearts, and we performed
unbiased gene array and metabolomics analyses to uncover
unidentified players in the regulation of mTOR-mediated
cardiac hypertrophy.
Materials and Methods
The data that support the findings of this study are available
to other researchers on request. All the materials used in this
study are available commercially from the indicated vendors.
Additional methods can be found in Data S1.
Animal Treatment
The University of North Carolina Institutional Animal Care
and Use Committee approved all protocols. Mice were
housed in a pathogen-free barrier facility (12-hour light/12-
hour dark cycle) with free access to water and food (Prolab
RMH 3000 SP76 chow). Mice with LoxP sequences inserted
on either side of exon 2 in the Acsl1 gene were backcrossed
6 times to C57BL/J6 mice and then interbred with mice in
which Cre expression is driven by an a-myosin heavy-chain
promoter induced by tamoxifen (B6.Cg-Tg(Myh6-cre/Esr1)
1Jmk/J, Jackson Labs) to generate tamoxifen-inducible,
heart-specific Acsl1 knockout (Acsl1H/) mice.14 At 6 to
8 weeks of age, Acsl1H/ and littermate Acsl1flox/flox
control male mice were injected intraperitoneally with
tamoxifen (75 mg/kg BW, Sigma) dissolved in corn oil
(20 mg/mL) for 4 consecutive days (3 mg/40 g of body
weight). Subgroups of mice were also injected daily
intraperitoneally for 2 weeks with rapamycin (Sigma,
1 mg/kg in PBS, 8% ethanol, 10% Tween 20, 10% PEG-
400) or with vehicle alone. Two weeks after tamoxifen
induction, animals were anesthetized with 2,2,2-tribro-
moethanol (Avertin) and tissues were removed and snap-
frozen in liquid nitrogen. To isolate total membranes, heart
ventricles were homogenized with 10 up-and-down strokes
using a motor-driven Teflon pestle and glass mortar in ice-
cold medium I (MedI) buffer (10 mmol/L Tris [pH 7.5],
1 mmol/L EDTA, 250 mmol/L sucrose, 1 mmol/L dithio-
threitol [DTT], plus HaltTM protease and phosphatase inhibitor
cocktail [ThermoScientific]). Homogenates were centrifuged
at 100 000g for 1 hour at 4°C; the membrane pellet was
then resuspended in MedI buffer. Protein content was
determined by the BCA assay (Pierce) with bovine serum
albumin (BSA) as the standard. Plasma was collected from
mice in 5% 0.5 mol/L EDTA. Plasma triacylglycerol, nones-
terified free fatty acids, glucose (Wako), and free and total
glycerol (Sigma) were measured with colorimetric assays.
Clinical Perspective
What Is New?
• We describe, for the first time, an intermediate phase of
cardiac metabolism whereby alternative downstream uses
of glucose are observed before the establishment of the
strictly glycolytic state that results from long-term inhibition
of fatty acid activation.
What Are the Clinical Implications?
• The hypertrophy observed in the early stages of a cardiac
metabolic switch resulting from partial Acsl1 ablation occurs
in the context of normal heart function and bears a
transcriptional signature that is reminiscent of physiological
hypertrophy, making this model particularly useful to study
the precise mechanisms underlying the imbalances in
cardiac remodeling that lead to pathological hypertrophy
and heart failure.
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Doppler analysis of the mitral valve to determine the inflow
velocity was performed on lightly anesthetized mice (2%
[vol/vol] isoflurane/100% oxygen) as previously
described.14,19,20 Mitral valve flow Doppler was acquired
by positioning the transducer angled cranially in a supine
mouse at 45° in an epigastric position to achieve an apical
4-chamber view. Peak E and A heights were determined on
mitral valve sequential waveforms in at least 5 waveforms.
The mean performance index was calculated as the
isovolumetric contraction time (ICT) plus the isovolumetric
relaxation time (IRT) divided by the ejection time
([ICT+IRT]/ET) to determine if either systolic or diastolic
dysfunction was present.21–25 Doppler measurement data
represent 3 to 6 averaged cardiac cycles from at least 2
scans per mouse.
ACSL Assay
ACSL-specific activity was measured as described.14 Briefly,
total membrane fractions were isolated by centrifuging
homogenized tissues at 100 000g for 1 hour at 4°C. Protein
(2–6 lg) was incubated with 50 lmol/L [1-14C]-palmitate,
10 mmol/L ATP, 250 lmol/L CoA, 5 mmol/L dithiothreitol,
and 8 mmol/L MgCl2 in 175 mmol/L Tris, pH 7.4 at room
temperature for 10 minutes to measure initial rates. The
enzymatic reaction was stopped with 1 mL of Dole’s solution
(heptane:isopropanol:1 mol/L H2SO4; 80:20:1, v/v); heptane
and water were added to separate the phases, and radioac-
tivity of the acyl-CoAs in the aqueous phase was measured in
a liquid scintillation counter. No ACSL activity was measurable
in the cytosolic fraction.
Global Gene Expression Analyses
Total RNA was isolated from heart ventricles (RNeasy Fibrous
Tissues Kit, Qiagen). RNA integrity was verified on an Agilent
BioAnalyzer 2100 (RIN ≥9). Gene expression microarrays
were used to analyze changes in gene expression at either 2
or 10 weeks of Acsl1 knockdown in mouse hearts. For
microarray analysis, cyanine-5-labeled cRNA was cohybridized
to the G4122F mouse whole genome array (Agilent) with
equimolar amounts of cyanine-3-labeled mouse reference
RNA26 and scanned on a GenePix 4000B (Axon) with Feature
Extraction (v9.5.3.1; Agilent). Total probes (9009) represent-
ing 7172 unique genes passed quality control (flagged as
detected in ≥70% of the samples) (see Table S1). One-way
ANOVA analysis was performed to determine differentially
expressed genes between genotypes, identifying 1244 probes
(only 62 probes expected by chance) satisfying a corrected P
value (Benjamini Hochberg false discovery rate) cutoff of
0.05. RNA sequencing (RNAseq) was used to analyze changes
in gene expression after 2 weeks of Acsl1 knockdown in
mouse hearts in the presence or absence of rapamycin.
Library preparation of mRNA was performed using the RNA
TruSeq Kit (Illumina), and 5 samples were randomly pooled
together and sequenced via 50 base single-end reads on a
HiSeq 2000 sequencer (Illumina). Aligned reads were sorted
and indexed using SAMtools27 and translated to transcrip-
tome coordinates, then filtered for indels, large inserts, and
zero mapping quality using UBU v1.0 (https://github.c
om/mozack/ubu). Transcript abundance estimates for each
sample were performed using RSEM28 and raw RSEM read
counts for all RNAseq samples were normalized to the overall
upper quartile (see Table S2). 21 711 genes were mapped;
the list was filtered to only include genes with a minimum
count of 100 in all 20 samples, resulting in 9118 total genes
for analysis. Three-way ANOVA analysis using the categorical
effects of genotype and drug, as well as the RNAseq lane as a
random effect was performed with an absolute fold change
minimum of 1.5 with a P<0.01 (Partek Genomics Suite v6.6).
Complete, MIAME (Minimum Information About a Microarray
Experiment)-compliant microarray and RNAseq data sets
were archived with the Gene Expression Omnibus of the
National Center for Biotechnology Information and are
accessible through the GEO SuperSeries accession No.
GSE103375.
Immunoblots
Total protein lysates were isolated in lysis buffer (20 mmol/L
Tris base, 1% Triton X-100, 50 mmol/L NaCl, 250 mmol/L
sucrose, 50 mmol/L NaF, 5 mmol/L Na2P2O7, plus Halt
TM
protease and phosphatase inhibitor cocktail [Thermo Scien-
tific]). Equal amounts of protein (100 lg) were loaded and
resolved on 10% SDS polyacrylamide gels and transferred to
nitrocellulose membranes. Blots were probed with antibodies
against ACSL1 (catalog No. 4047), phosphorylated p70 (P-
p70) S6 kinase (S6K) (catalog No. 9234), phosphorylated 4E-
BP1 (catalog No. 2855), and phosphorylated AMP-activated
protein kinase (P-AMPK) (catalog No. 2531), and were then
stripped and reprobed with p70 S6K (catalog No. 9092), 4E-
BP1 (catalog No. 9644), or AMPKa (catalog No. 2532)
antibodies, respectively (all antibodies from Cell Signaling).
GAPDH (Abcam, catalog No. ab8245) was used as loading
control.
Histology
Heart ventricles were fixed for 24 hours in PBS containing 4%
paraformaldehyde, transferred to 70% ethanol, embedded in
paraffin, serial sectioned, and stained with Masson’s
trichrome. Slides were scanned using an Aperio ScanScope
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(Aperio Technologies, Vista, CA) and fibrosis was quantified
using Aperio ImageScope (v12.3.2.8013). The Positive Pixel
Count v9 algorithm was used to measure staining of collagen
(representing both fibrosis and collagen in extracellular matrix
[ECM]), with hue value and width of 0.66 and 0.1, respec-
tively.29 The N positive/N total value representing the
percentage of collagen of the entire section was used to
determine the weighted average for each slide, expressed as
percentage of fibrosis.
2-Deoxyglucose and 2-Bromopalmitate Uptake
Anesthetized mice were injected intraperitoneally with 5 lCi
2-deoxy[1-14C]-glucose in saline or retro-orbitally with 1.5 lCi
2-bromo-[1-14C]-palmitate complexed to BSA in PBS (Moravek
Biochemicals). Tissues were harvested and flash frozen in
liquid nitrogen 30 minutes after injection. Radioactivity was
measured in tissue homogenates by scintillation counting and
normalized to the number of disintegrations per minute (DPM)
present in 5 lL of serum obtained 5 minutes after injection
([dpm/mg tissue]/dpm in 5 lL serum).
Metabolomic Analysis
Detailed methods for tissue sample preparation and analysis
by gas or liquid chromatography/mass spectrometry as well
as the raw, processed, and normalized data are available at
the Carolina Digital Repository (https://doi.org/10.17615/
c6794k). Metabolite concentrations were analyzed using
Metaboanalyst (v3.0)30–32 run in the statistical package R
(v3.3.2). Concentrations were log transformed and unit
scaled, resulting in a Gaussian distribution of metabolite
concentrations (Figure S1). The normalized data were used for
principal component analysis and 2-way ANOVA analyses to
identify metabolites that associated with genotype or
rapamycin treatment (see Table S3). Pearson correlation
coefficients were calculated to measure the relationship
between heart weight (normalized to body weight, resulting in
a normal distribution) and each normalized metabolite
concentration (Figure S1).
Statistical Analysis
Values are expressed as the meanstandard error of the
mean (SEM) as indicated. For studies that included rapamycin
treatments, 2-way ANOVA was used with the genotype and
treatment identified as the sources of variation. Post-hoc
tests were performed with Tukey’s multiple comparisons test.
For all tests, P>0.05 was considered nonsignificant (ns). All
variables used for correlation analyses (Pearson) were con-
tinuous and normally distributed, and linear relationships were
confirmed via scatterplot analysis.
Results
Partial ACSL1 Ablation in the Heart was Sufficient
to Induce Cardiac Hypertrophy But Did Not Affect
Cardiac Function
Analysis of Acsl1H/ hearts 10 weeks after tamoxifen
induction of cardiac-specific ACSL1 deficiency results in
>90% reduction in total ACS activity and FA oxidation.14
This markedly decreased ability to activate FA is accompa-
nied by a compensatory increase in glucose uptake,
consistent with a shift toward glycolytic oxidation, as well
as the development of mTOR-responsive hypertrophy with
diastolic dysfunction.14,15 Treatment with the mTOR inhi-
bitor rapamycin for 10 weeks prevents the development of
hypertrophy, whereas diastolic dysfunction and glucose
uptake are not affected.15 To determine the initial effects of
decreasing ACSL1 activity, we assessed the effects of a
partial Acsl1 knockdown on the same parameters of cardiac
metabolism and function 2 weeks after tamoxifen injection,
when ventricular Acsl1 mRNA was reduced by 88%
(Figure 1A). At this time, ACSL1 protein levels (Figure 1B)
and total ACS activity (Figure 1C) had decreased by 52%
and 70%, respectively, highlighting the relatively high
stability of the ACSL1 protein as well as its role as the
major FA-activating enzyme in the heart. Lack of AMPK
activation in Acsl1H/ knockdown hearts (Figure 1D)
suggested that the compensatory processes triggered in
response to the impaired FA oxidation were sufficient to
maintain adequate cellular ATP/AMP ratios. However, the
partial knockdown of ACSL1 observed 2 weeks after
tamoxifen induction was sufficient to elicit cardiac hyper-
trophy in vehicle-treated Acsl1H/ hearts (Figure 1E),
whereas hypertrophy was not observed in hearts treated
concomitantly with rapamycin, indicating that mTOR also
mediates the compensatory hypertrophy observed at this
early time point in the cardiac fuel switch. At this time
point in the metabolic switch, phosphorylation of down-
stream mTORC1 targets S6K and 4E-BP1 showed marked
variation (Figure 1F), suggesting that mTORC1 activation, as
measured by posttranslational modifications, occurs gradu-
ally. Doppler analysis of mitral and aortic valve blood flow
did not identify differences in the mitral valve E/A ratio in
Acsl1H/ knockdown compared to control hearts 2 weeks
after tamoxifen treatment, indicating that cardiac function
was not affected by partial ACSL1 ablation (Figure 1G).
Mean performance index calculations showed a mild
rapamycin effect in both control and Acsl1 knockdown
animals. Non–statistically significant functional issues were
also identified but were considered to be of little relevance
because no diastolic dysfunction is evident at this time
point.
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Knockdown of ACSL1 Resulted in Cardiac-
Specific Metabolic Derangements That Did Not
Affect Systemic Metabolic Homeostasis
Acsl1 knockdown had no effect on blood glucose, whereas
levels of circulating nonesterified FAs, free glycerol, and
triacylglycerol showed mild, albeit non–statistically significant
alterations, suggesting that cardiac-specific knockdown of
Acsl1 did not affect systemic metabolic homeostasis
(Figure 2A). In contrast, the partial knockdown of ACSL1
resulted in dramatic changes in cardiac substrate uptake. The
inability of Acsl1H/ hearts to activate and therefore trap FA
within cardiomyocytes resulted in a >50% reduction in
2-bromo[1-14C]-palmitate uptake (Figure 2B), whereas
2-deoxy[1-14C]-glucose uptake was significantly higher
despite the high variability exhibited by Acsl1H/ hearts
(Figure 2C).
Short-Term Inactivation of ACSL1 Caused
Transcriptional Derangements That Were Distinct
From Those Resulting From Total ACSL1
Knockout Observed 10 Weeks After Tamoxifen
Induction
We analyzed global changes in cardiac gene expression after
2 and 10 weeks of Acsl1 knockdown in cardiomyocytes;
control hearts included in this analysis were obtained from
Figure 1. Short-term Acsl1 inactivation induces cardiac hypertrophy before the cardiac dysfunction
develops. Ventricular Acsl1 mRNA (A), ACSL1 protein levels (B), ACS activity (C), AMPK (D) and mTORC1
(F) activation 2 weeks after tamoxifen treatment. E, Relative heart weight (heart weight/body weight) in
control and Acsl1H/ mice treated with vehicle (Veh) or rapamycin (Rapa). Body weights were not
significantly affected by Acsl1 knockdown or rapamycin treatment. F, mTOR activation via phosphorylation
of downstream targets S6K and 4E-BP1. G, E/A ratio (ratio between early (E) and late (atrial-A) ventricular
filling velocity) and MPI (mean performance index) in control and Acsl1H/ mice. n=3 to 5 per group.
MeansSEM (error bars). *P≤0.05, **P≤0.01 compared with littermate controls.
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Acsl1flox/flox control mice injected in parallel and harvested at
the same time points of 2 and 10 weeks. Correlation analyses
(Figure 3A) identified 3 distinct sample groups: 10-week
Acsl1H/ knockout, 2-week Acsl1H/ knockdown, and an
interspersion of 10- and 2-week Acsl1flox/flox control hearts.
One-way ANOVA analysis identified 1244 differentially
expressed genes; all genes with a change ≥1.5-fold in any
pairwise comparison (Figure 3B) were clustered to identify
patterns of gene expression among the 3 groups. The
resulting heatmap shows a predominant signal for the 10-
week Acsl1H/ knockout hearts, with distinct clusters of
probes that were markedly altered after only 2 weeks of Acsl1
knockdown compared with either complete Acsl1 knockout at
10 weeks or to Acsl1flox/flox control hearts (Figure 3C).
We next looked at the expression of rapamycin-sensitive
genes previously identified in 10-week Acsl1H/ knockout
hearts15,18 to determine if these transcriptional responses
were evident after short-term Acsl1 inactivation (Figure 4A).
Surprisingly, this collection of genes did not appear to
represent an intermediate phenotype of mTOR activation. We
analyzed the expression of pathological hypertrophy markers,
amino acid responsive genes, metabolic genes and oxidative
stress markers that had previously been shown to be
regulated by mTOR15,18 (Table 1). Expression of pathological
Figure 2. Knockdown of ACSL1 results in cardiac-specific metabolic derangements that do not affect
systemic metabolic homeostasis. A, 4-hour-fasting plasma non-esterified fatty acids (NEFA), glycerol,
triglycerides (TAG), and glucose levels in control and Acsl1H/ mice treated with vehicle (Veh) or
rapamycin (Rapa). B, Uptake of 2-bromo[1-14C]palmitate in ventricles of control and Acsl1H/ knockdown
mice treated with vehicle or rapamycin after a 4 hours fast. C, Ventricular 2-deoxy[1-14C]-glucose uptake in
control and Acsl1H/ hearts. n=3 to 8 per group. The values reported are meansSEM (error bars).
*P≤0.05 compared with littermate controls.
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hypertrophy markers in Acsl1H/ knockdown hearts differed
from the results observed after complete Acsl1 knockout,
suggesting that the hypertrophy observed at this early time
point in the metabolic switch was still compensatory. The
expression of amino acid–responsive genes also remained
unaffected in Acsl1 knockdown hearts, in contrast to what
had been observed after complete Acsl1 ablation. Expression
of genes involved in glucose and lipid metabolism showed
intermediate effects compared with ACSL1 knockout hearts
(Table 1), consistent with a transitional point in the cardiac
substrate switch. In addition, the expression of oxidative
stress markers differed markedly between the 2 models of
Acsl1 deficiency.
We compared gene expression changes in the 2-week
Acsl1H/ knockdown hearts to those of either control or 10-
week Acsl1H/ knockout hearts to determine which genes
were exclusively affected during the early stages of the
metabolic fuel switch (Figure 4B). We observed a dramatic
upregulation of genes involved in ECM remodeling and cell-
cell or cell-matrix interactions, strong indicators of fibrosis. In
addition, despite the observed increase in glucose uptake that
results from partial ablation of Acsl1, these hearts did not
exhibit a glycolytic signal (Figure 4C), suggesting that the
residual ACSL activity present in Acsl1H/ knockdown
hearts may be sufficient for contractile energy production.
Alternatively, the partial block in FA activation that results
Figure 3. Microarray gene chip analyses demonstrate that the partial ablation of Acsl1 causes
transcriptional derangements that are distinct from those caused by total ACSL1 knockout observed 10-
week after tamoxifen treatment. A, Correlation of 8706 probes identifying 3 distinct groups: 10-week
Acsl1H/ knockout, 2-week Acsl1H/ knockout, and a combination of 10- and 2-week Acsl1flox/flox
controls. B, Venn diagram of gene expression overlap with a fold-change ≥1.5. C, Unsupervised hierarchical
clustering analysis of 1244 genes (columns) from 17 samples (rows) using the Euclidian matrix with average
linkage (Partek Genomics Suite, v6.6). Three primary clusters of samples comprised solely of Acsl1flox/flox,
10-week Acsl1H/, or 2-week Acsl1H/ biological replicates were identified. The genes portioned into 2
groups of higher (yellow) or lower (blue) expression across the 3 sample groups.
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from incomplete Acsl1 knockdown may result in the initial use
of alternative metabolic substrates before the switch to
glucose is complete 10 weeks after the Acsl1 knockout is
induced.14,15
Rapamycin Treatment Identified Novel Cardiac-
Specific mTOR Targets Involved in the Initial
Stages of the Cardiac Metabolic Switch
To further investigate the effects of partial Acsl1 ablation on
cardiac metabolism, we used RNAseq to examine global
changes in cardiac gene expression after 2 weeks of
cardiomyocyte-specific Acsl1 knockdown plus concomitant
vehicle or rapamycin treatments. Of the 9118 total genes
that passed quality control, 145 genes exhibited a change
≥1.5-fold in Acsl1H/ knockdown hearts compared with
littermate controls (2-way ANOVA analyses; see Table S2).
Partial Acsl1 ablation resulted in the expected changes in
lipid metabolism gene expression, with decreased FA uptake,
intracellular FA transport, and triacylglycerol synthesis, as
well as compensatory increases in peroxisomal and mito-
chondrial oxidation gene expression. Notably, no compen-
satory changes occurred in the expression of other activities
that synthesize acyl-CoAs (Figure 5A). Acsl1 knockdown
hearts exhibited suppressed glucose transporter 1 and
glucose transporter 4 expression despite activation of
glucose transport regulators and the observed increase in
2-deoxy[1-14C]-glucose uptake (Figure 5B), a phenomenon
we also observed in 10-week Acsl1 knockout hearts as
well as in a skeletal-muscle–specific model of ACSL1
deficiency.17,18 RNAseq analyses once again showed shifts
in glucose metabolism gene expression toward a downreg-
ulation of glycolysis and glycogen breakdown (Figure 5B). In
contrast, genes involved in the pentose phosphate and
hexosamine biosynthetic pathways were significantly
increased (Figure 5C), suggesting that the excess glucose
imported may, in fact, be diverted to these alternative routes
rather than used to produce energy. Alterations in the
Figure 4. The early stages of the metabolic switch are accompanied by increased expression of fibrosis
markers and no upregulation of the glycolytic program. Expression of rapamycin-sensitive mTOR genes
identified in 10-week Acsl1H/ knockout hearts compared to 2-week Acsl1H/ knockdown and control
hearts (A). Expression of 2-week centric genes suggests increased ECM/fibrosis (B) and is not indicative of
a switch towards glycolytic metabolism (C). n=3 to 8 per group. The values reported were determined using
microarray gene chips and are represented by the meanSEM (error bars). *P≤0.05; **P<0.01; †P<0.001;
‡P<0.0001 compared with littermate controls.
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expression of genes involved in the tricarboxylic acid cycle
(Figure 5D) and in amino acid metabolism and ketogenesis
(Figure 5E) also indicated a shift toward the use of alternate
energy substrates during the early stages of the cardiac fuel
switch. Rapamycin treatment resulted in differential effects
between control and Acsl1H/ knockdown hearts but
reverted the observed changes in several genes (denoted
by ▲), revealing novel mTOR targets involved in cardiac
metabolism. Of note, Eno1 and Glud1 have been shown to be
upstream of mTOR activation in cancer models,33,34 whereas
hepatic CD36 is known to be regulated by rapamycin but in
an opposite manner to that observed in Acsl1H/ knock-
down hearts.35 Other novel cardiac targets of mTOR uncov-
ered by this study include Pdha and Dbt, components of the
pyruvate dehydrogenase and branched-chain ketoacid dehy-
drogenase complexes, respectively.
Acsl1 Knockdown Results in a Transient Increase
in Cardiac Fibrosis That is Unrelated to the
Development of Hypertrophy
RNAseq analysis of Acsl1 knockdown hearts confirmed the
upregulation of fibrosis genes observed in microarray analy-
ses comparing 2- and 10-week cardiac-specific ACSL1
ablation (Figure 6A, Figure S3), which was further corrobo-
rated by Masson’s trichrome staining (Figure 6B). Transcrip-
tional alterations in the fibrotic program were observed in
both the 10-week cardiac-specific Acsl1 knockout and 2-week
knockdown models; however, the induction of fibrosis genes
was significant only in the short-term model (Figure 6C).
Moreover, partial ACSL1 ablation resulted in significant
induction of genes involved in ECM breakdown, which could
explain why complete cardiac ablation of ACSL1 does not
result in increased fibrosis.14
We questioned whether the observed induction in ECM
biogenesis and organization that is predominant in the short
Acsl1 inactivation model is linked to the development of
hypertrophy during the early stages of the cardiac substrate
switch. Despite the drastic differences in the expression of
pathological hypertrophy markers between the 2 ACSL1
deficiency models examined (Table 1), rapamycin treatment
prevented the development of hypertrophy in this model;
however, it did not reverse the Acsl1-dependent alterations in
the expression of fibrosis markers, indicating that the
upregulation of fibrosis does not underlie the mTORC1-
mediated hypertrophy observed in Acsl1 knockdown hearts.
In direct contrast with a total absence of cardiac ACSL1,
partial Acsl1 ablation did not result in increased expression of
pathological hypertrophy markers (Table 1, Figure 6D).
Instead, we observed rapamycin-sensitive changes in the
expression of genes associated with physiological hypertro-
phy, and a shift toward increased expression of myosin heavy
chain-b.
Short-Term Acsl1 Inactivation Caused a Clear and
Unique Change in the Cardiac Metabolic
Fingerprint
We analyzed changes in the cardiac metabolome during the
early stages of the metabolic switch induced by FA oxidation
inhibition. Metabolomic analysis identified 64 metabolites
that were significantly altered in hearts exhibiting reduced
ACSL1 activity (Figure 7A), with some overlapping as well as
unique changes compared with the 10-week model of cardiac
ACSL1 absence.18 Moreover, concomitant treatment with the
mTOR inhibitor rapamycin reverted the metabolic signature
attributed to Acsl1 inactivation in pathways involved in amino
acid and pentose shunt metabolism. Surprisingly, metabolic
intermediates involved in FA synthesis and lysophospholipids
Table 1. Gene Expression Changes After 2 and 10 Weeks of











Myc 1.000.23 0.540.19 5.040.59*
a-Ska 1.000.33 3.601.71 5.930.71*
Acsl3 1.000.36 1.910.95 2.850.41*
Bnp 1.000.18 1.500.05* 2.060.094‡




Fgf21 1.000.26 2.210.28 18.400.36§
Mthfd2 1.000.29 3.131.64 12.801.42†
Asns 1.000.26 1.000.23 4.670.34§
Slc7a5 1.000.23 0.640.11 2.900.09§
Metabolism Hif1a 1.000.35 3.841.77 10.031.20*
Cd36 1.000.23 0.540.40 2.280.28‡
Srebf1 1.000.23 2.200.07* 6.030.23§
mCpt1 1.000.33 2.180.35* 5.900.54‡
Ppara 1.000.26 0.240.68 2.450.44†
Acot1 1.000.33 1.890.20* 3.920.21§
Acot2 1.000.31 2.690.52* 6.860.28§
Oxidative
stress
Gsta2 1.000.38 1.200.45 8.060.32§
Gsta1 1.000.20 1.040.11 3.840.19§
Gdf15 1.000.29 2.110.25* 5.020.12§
Sesn1 1.000.36 0.020.56 4.280.75§
Gstm5 1.000.57 0.070.68 1.690.60*
Gstk1 1.000.31 1.420.36† 1.560.46†
mGst1 1.001.17 3.630.69§ 0.110.66
Relative fold change in gene expression was determined via microarray analysis, n=3 to
8 per group, represented by the meanSEM.
*P≤0.05; †P<0.01; ‡P<0.001; §P<0.0001 compared with control hearts.
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were also normalized by rapamycin treatment. As observed in
our RNAseq analyses, rapamycin affected the levels of some
metabolites in Acsl1flox/flox control hearts; however, PCA
suggested that treatment with rapamycin normalizes the
changes observed in metabolites in Acsl1H/ knockdown
hearts but has little effect on cardiac metabolites in control
mice (Figure 7B).
The variability in glucose uptake of Acsl1H/ knockdown
hearts prompted us to investigate the changes in the
metabolic profile of hearts during the early stages of the
substrate switch. We observed a negative correlation
between glucose uptake and heart size (Table 2), suggesting
that hearts do not become hypertrophied if they can
compensate for their inability to use FA by rapidly switching
to glucose use. Correlations of metabolites identified via
metabolomic analysis and corresponding heart sizes revealed
that levels of metabolites involved in glycogenolysis, glycol-
ysis, and protein glycosylation decreased with heart size,
Figure 5. Rapamycin treatment reveals novel mTOR targets of cardiac metabolism. A, Partial Acsl1
knockdown resulted in suppression of FA transport and triacylglycerol synthesis, whereas peroxisomal and
mitochondrial oxidation gene expression was induced. B, Acsl1 knockdown hearts exhibit decreased
glycolytic (Gpi, Alfoa, Gapdh, Ldha) and glycogen degradation (Pygm, Phkg1) genes. C, Glucose is directed
towards the pentose phosphate (Rpe, Rpia) and hexosamine biosynthesis (Gfprt1, Oga (protein
glycosylation)) alternative metabolic pathways. D, Tricarboxylic acid cycle flux and anaplerosis, and (E)
ketogenesis and amino acid metabolism are induced in response to partial Acsl1 ablation. n=5 per group.
The values reported were determined using RNAseq and are represented by the meanSEM (error bars).
*P≤0.05; **P<0.01 compared with littermate controls; ▲ denotes genes whose altered expression in
Acsl1H/ knockdown hearts was reverted by rapamycin treatment; denotes genes whose expression
was altered by rapamycin treatment in Acsl1flox/flox control hearts.
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whereas amino acid, ATP catabolism, and anaplerotic
metabolites levels increased in hypertrophied hearts
(Table 3).
Discussion
We used unbiased metabolomics and gene expression
analyses to examine the early cellular responses to altered
cardiac substrate availability and to establish whether the
underlying mechanisms that promote the development of
cardiac hypertrophy are glucose-mediated. Our results indi-
cate that even partial deficiency of ACSL1 is sufficient to elicit
cardiac hypertrophy; because rapamycin prevented the
hypertrophy, we questioned whether enhanced glycolytic flux
underlies the development of an mTOR-mediated process.
Changes in the uptake of nonmetabolizable FA and glucose
analogs in Acsl1 knockdown hearts were comparable to those
observed 10 weeks after temporal induction of ACSL1
knockout, suggesting that a residual ACS activity of 30% is
not sufficient to sustain normal cardiac metabolism, forcing a
metabolic switch. Long-term treatment with rapamycin induced
glucose intolerance in the 10-week Acsl1 inactivation model,15
but this effect was not observed after 2 weeks of treatment
with the mTOR inhibitor, indicating that inhibition of mTORC2-
mediated protein kinase B phosphorylation is circumvented in
the partial Acsl1 inactivation model. We did not observe
consistent activation of the mTORC1 downstream targets S6K
or 4E-BP1, suggesting that variability in attaining the threshold
level required to activate mTORC1 at this early time point in the
cardiac metabolic switch correlates with the variability
observed in substrate uptake and metabolism in Acsl1 knock-
down hearts. However, suppression of the mTORC1 inhibitors
Deptor and Rptor and alterations in mTOR-regulated autophagy
genes (Figure S2), as well as the response to rapamycin
treatment of various genes analyzed, confirmed that mTOR is
indeed activated by partial Acsl1 ablation.
Figure 6. Increased cardiac fibrosis is not related to the development of hypertrophy in the early stages
of the metabolic switch. A, RNAseq analysis of Acsl1-dependent alterations in the expression of genes
involved in collagen fiber or glycoprotein synthesis (Col14a1, Gpc6, Matn2), cell-cell and cell-matrix
interactions (Cfh, Adam19, Adamtsl2, Ecm2, Adam11, Thbs2, Fndc3a), ECM degradation (Htra1, Sulf1), and
regulation of ECM dynamics (Pdgfra and Wisp2/CCN5). B, Masson’s trichrome staining of control and Acsl1
knockdown hearts in the absence and presence of rapamycin treatment. Original magnification, 920; scale
bar=100 lm. C, Comparison of the relative expression of genes involved in ECM synthesis and degradation
determined by microarray analysis in the 2-week ACSL1 knockdown vs 10-week knockout models. D, The
effects of ACSL1 inactivation on the expression of genes involved in physiological hypertrophy in the early
stages of the metabolic switch as measured by RNAseq. n=5 per group. The values reported are
meansSEM (error bars). *P≤0.05; **P<0.01; ‡P<0.0001 compared with littermate controls; ▲ denotes
genes whose altered expression in Acsl1 knockdown hearts was reverted by rapamycin treatment.
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Despite the observed activation of mTORC1, metabolomic
analyses at 2 weeks confirmed a downregulation of glycolytic
intermediates during the early stages of the forced substrate
switch, and an absence of the strong transcriptional glycolytic
signal exhibited by Acsl1 knockout hearts. Instead, we
observed an increase in alternative downstream uses of
glucose; in addition to energy production, both our global
gene expression and metabolomics analyses suggest that the
excess imported glucose may be partially directed toward
hexosamine and ECM biosynthesis, protein O-/N-GlcNAcyla-
tion, and the pentose phosphate shunt (Figure 8). Given that
other studies have also observed changes in hexosamine
biosynthesis and protein O-GlcNAcylation in response to
alterations in cardiac metabolism36 and hypertrophy,37 further
study of these changes is warranted. In addition to the
observed diversion of glucose toward alternative downstream
fates, glucose metabolism correlated negatively with heart
size. Thus, contrary to reports in other models that associate
glucose metabolism with the development of mTOR-mediated
hypertrophy,13 our results suggest that increased use of
glucose was more prominent in hearts that were not
hypertrophied. Finally, rapamycin treatment blocked the
development of hypertrophy, but had no effect on glucose
uptake rates. Taken as a whole, these data indicate that in
this model, at least initially, the use of glucose was not
directly responsible for the development of hypertrophy.
As expected, the partial block in FA activation resulting
from Acsl1 knockdown led to the accumulation of FA and
other lipid intermediates, with a predominance of lysophos-
pholipids. A second dominant class of metabolites included
amino acids and intermediates of amino acid metabolism.
Amino acids can regulate the activity and downstream effects
of mTORC1 on protein translation and cell growth. Increased
amino acid metabolism, particularly that of cysteine and
glutathione, was also observed in the 10-week Acsl1 ablation
model and was presumed to be triggered to control excessive
reactive oxygen species production from oxidative
phosphorylation.18 Oxidative stress markers were not as
consistently upregulated in the partial Acsl1 inactivation
model, suggesting that the increase in amino acid metabolism
was independent of oxidative stress. Therefore, the increase
in cysteine and glutathione metabolism observed in the 10-
week ACSL1 knockout model may have been elicited in
Figure 7. Partial ACSL1 ablation results in cardiac-
specific metabolic derangements that are reverted
by rapamycin. A, Unsupervised hierarchical cluster-
ing of 64 metabolites identified by 2-way ANOVA. B,
Principal component analysis (PCA) of cardiac
metabolite concentrations in control and Acsl1H/
mice treated with vehicle (Veh) or rapamycin (Rapa).
The first 2 components are shown. Confidence
ellipses categorized by genotype9treatment repre-
sent 2 standard deviations. n=6 to 8 per group.
Table 2. Glucose Uptake and Heart Size Correlation
Heart % BW
Glucose
Uptake (DPM/g) Correlation Coefficient P Value
Vehicle Acsl1flox/flox 0.4100.01 34.03.4 0.877 0.022
Acsl1H/ 0.4790.023* 103.233.6 0.730 0.040
Rapamycin Acsl1flox/flox 0.4370.031 38.94.7 No correlation N/A
Acsl1H/ 0.4600.020 103.529.2 No correlation N/A
The Pearson correlation coefficient and the corresponding P value of the association between heart weight (as a percentage of body weight, BW) and cardiac glucose uptake measured by
radiolabeled glucose activity per gram of tissue (DPM/g). Associations were tested in either control animals (Acsl1flox/flox) or in animals lacking cardiac Acsl1 (Acsl1H/) for 2 weeks,
treated with either rapamycin or vehicle control (n=3–8 per group); N/A, not applicable
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response to the initial switch toward the use of amino acids
during the early stages of the metabolic switch.
Rapamycin treatment resulted in a marked attenuation of
the Acsl1-dependent alterations in the expression of various
genes involved in metabolic processes. In addition, rapamycin
had opposing effects on the expression of several genes
involved in glucose and pentose phosphate metabolism,
ketogenesis, and tricarboxylic acid cycle flux in Acsl1
knockdown hearts, suggesting that the ACSL1-dependent
generation of a specific metabolite may contribute to cardiac-
specific mTORC1 signaling in the early stages of the
metabolic substrate switch. Confirming this notion, the
opposing effects of rapamycin treatment were also observed
in lysophospholipid, pentose phosphate shunt, and amino acid
metabolites.
The premise of this study was to compare changes in
gene expression and metabolites in Acsl1 knockdown versus
Acsl1 knockout hearts in an effort to elucidate the precise
mechanism underlying mTOR activation and the development
of hypertrophy. Acsl1 knockdown hearts became hypertro-
phied during the first 2 weeks of the metabolic switch, and
rapamycin treatment prevented this change. The striking
induction of fibrosis-related genes we observed exclusively in
Acsl1 knockdown hearts seemed to be a likely candidate for
such a regulator of hypertrophy; however, both the tran-
scriptional induction of fibrosis and increased collagen
staining are absent in ACSL1 knockout hearts.14 Therefore,
we hypothesize that the transient effect on ECM remodeling
observed in the early stages of the metabolic switch might
occur to increase cell-cell interactions and thereby enhance
transport of nutrients from the surrounding endothelial cells.
The concomitant upregulation of ECM synthesis and degra-
dation genes in the partial Acsl1 inactivation model suggests
that this is a highly dynamic process; rapid reversal might
explain the lack of fibrosis once the switch to glucose
metabolism is complete. Rapamycin treatment did not revert
the altered expression of fibrosis genes to control levels,
implying that this process is not mediated by mTOR. In
contrast, mTOR inhibition prevented the development of
hypertrophy in Acsl1 knockdown hearts, further suggesting
that increased fibrosis does not underlie the development of
hypertrophy observed.
Table 3. Heart Metabolites and Heart Size Correlation
Decrease With Heart Size Corr. Coeff. P Value
Increase With
Heart Size Corr. Coeff. P Value
Fructose-1,6-diphosphate 0.618 0.0005 Tryptophan 0.676 0.0001
Glucose-6-phosphate 0.604 0.001 Phenylalanine 0.603 0.001
Glucose-1-phosphate 0.591 0.001 Propionylcarnitine 0.589 0.001
Mannose-6-phosphate 0.585 0.001 Tyrosine 0.561 0.002
Inosine-50-monophosphate 0.528 0.004 Hypoxanthine 0.552 0.002
Glycerol-3-phosphate 0.475 0.011 Fumarate 0.514 0.005
Fructose-6-phosphate 0.463 0.013 Asparagine 0.514 0.005
Acetylcarnitine 0.461 0.014 Arginine 0.483 0.009
S-adenosyl homocysteine 0.450 0.016 Isoleucine 0.468 0.012
a/c linoleate (18:3n3 or 6) 0.443 0.018 Urea 0.446 0.017
Uridine 0.437 0.020 Citrate 0.438 0.020
5-aminovalerate 0.432 0.022 Guanosine 0.415 0.028
Mannose 0.418 0.027 2-palmitoyl
phosphoethanolamine
0.406 0.032
Maltotetraose 0.412 0.030 Cysteine-glutathione
disulfide
0.401 0.034
Maltopentaose 0.405 0.032 Uracil 0.399 0.036
Fructose 0.401 0.034 AMP 0.398 0.036
Glucose 0.395 0.038 Inosine 0.381 0.045
GMP 0.382 0.045 Cysteine 0.375 0.050
S-lactoylglutathione 0.375 0.049
The Pearson correlation coefficient and the corresponding P value of the association between heart size (normalized to body weight) and the indicated metabolite. Data were from control
animals (Acsl1flox/flox) or animals lacking cardiac Acsl1 (Acsl1H/) for 2 weeks after treatment with either rapamycin or the vehicle control (N=27). Corr. Coeff indicates correlation
coefficient.
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Expression of pathological hypertrophy markers in Acsl1
knockdown hearts was not consistent with the results
observed in the 10-week total knockout model. Moreover,
whereas pathologically stressed hearts may initially compen-
sate, markers of physiological hypertrophy should not be in
evidence. However, we observed a significant increase in
myosin heavy chain-b expression that did not alter the myosin
heavy chain-b/a ratio, an adaptive response thought to
preserve function by increasing myocardial efficiency.38
Physiological and pathophysiological hypertrophies are gen-
erally described as separate conditions rather than as different
phases. However, this dichotomous classification may be an
oversimplification, particularly in the context of a model in
which progression of the stimulus (long-term ACSL1 inhibition)
results in mTOR-mediated pathological hypertrophy and
diastolic dysfunction. We therefore posit that the hypertrophy
observed in the early stages of a metabolic switch imposed by
partial Acsl1 knockdown is more reminiscent of a physiological
process and likely subject to distinct regulation by a novel
mTOR-regulated calcineurin B homologous protein 3/tescalcin
(CHP3)-glycogen synthase kinase-3a (GSK3a)- CCAAT enhan-
cer-binding protein (C/EBP) axis. Knockdown of Chp3
expression results in cardiomyocyte hypertrophy, increased
expression of the pathological hypertrophy marker atrial
natriuretic factor (the single pathological marker observed to
be significantly increased in the short Acsl1 ablation model),
and elevated GSK3a phosphorylation, suggesting that CHP3
functions as a negative regulator of hypertrophy via inhibition
of GSK3a/b phosphorylation and subsequent activation.39 In
addition, the cAMP response element–binding protein (CREB)
transcriptional activator, C/EBP, is thought to play a role in
physiological cardiac growth and protect against pathological
hypertrophy.40 Decreased CREB function is associated with
pathological hypertrophy, whereas reactivation by C/EBP
stabilizes adaptive hypertrophy.41 C/EBP is also known to be
regulated by mTOR in adipocytes42 and has been proposed as
a GSK3a regulator.43 We observed decreased CHP3, GSK3a,
and C/EBP expression in our model of partial Acsl1 deficiency,
whereas rapamycin treatment reverted the altered expression
levels of GSK3a and C/EBP. Based on our findings, we
hypothesize that mTOR-mediated inhibition of GSK3a induces
a partial hypertrophy phenotype. Understanding this molecular
switch will be important for the development of future
therapies, as it can help identify new molecular players in
Figure 8. Acsl1-dependent changes in metabolic pathways during the early stages of the cardiac metabolic switch. Metabolite concentrations
are identified as either increased (yellow) or decreased (blue) in Acsl1H/ hearts relative to control hearts. Upregulated (green) and
downregulated (red) genes are also shown. Metabolites and genes in gray were not identified in our metabolomic or gene expression analyses.
3-PG indicates 3-phosphoglycerate; ACAC-CoA, acetoacetyl-CoA; Arg, arginine; Asn, asparagine; Asp, aspartate; Cit, citrate; Cys, cysteine; F-1,6-
BP, fructose-1,6-bisphosphate; Fum, fumarate; G3P, glycerol 3-phosphate; Glc, glucose; Gln, glutamine; Glu, glutamate; Guo, guanosine; HMG-
CoA, 3-hydroxy-3-methylglutaryl-CoA; Ino, inosine; LysoPEs, lysophosphatidylethanolamine species; Mal, malate; Met, methionine; OAA,
oxaloacetate; Orn, ornithine; PI, phosphatidylinositol species; Ru5P, ribulose-5-phosphate; S7P, sedoheptulose-7-phosphate; X5P, xylulose-5-
phosphate; a-KG, a-ketoglutarate; b-HB, b-hydroxybutyrate. ▲ denotes genes and metabolites whose altered levels in Acsl1 knockdown hearts
was reverted by rapamycin treatment.
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the progression of adaptive to pathological hypertrophy that
may be suitable for therapeutic intervention.
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Supplemental Methods/Data S1 
Sample preparation for metabolomics (Metabolon) 
Experimental design.  Global biochemical profiles were determined in 27 samples of mouse 
ventricles from Acsl1flox/flox control or Acsl1H-/- animals left untreated or treated with rapamycin for 
two weeks.  Following receipt, samples were inventoried, and immediately stored at -80oC.  The 
extracted samples were split into equal parts for analysis on the GC/MS and LC/MS/MS platforms. 
Also included were several technical replicate samples created from a homogeneous pool 
containing a small amount of all study samples (“matrix”). 
Instrument and Process Variability.  Instrument variability was determined by calculating the 
median relative standard deviation (RSD) for the internal standards that were added to each 
sample prior to injection into the mass spectrometers.  Overall process variability was determined 
by calculating the median RSD for all endogenous metabolites (i.e., non-instrument standards) 
present in 100% of the matrix samples, which are technical replicates of pooled samples. 
Sample Preparation.  The sample preparation process was carried out using the automated 
MicroLab STAR® system from Hamilton Company.  Recovery standards were added prior to the 
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first step in the extraction process.  Sample preparation was conducted using a proprietary series 
of organic and aqueous extractions to remove the protein fraction while allowing maximum 
recovery of small molecules.  The resulting extract was divided into two fractions; one for analysis 
by LC and one for analysis by GC.  Samples were placed briefly on a TurboVap® (Zymark) to 
remove the organic solvent.  Each sample was then frozen and dried under vacuum.  Samples 
were then prepared for the appropriate instrument, either LC/MS or GC/MS.  For QA/QC purposes, 
a number of additional samples were included with each day’s analysis.  A selection of QC 
compounds was also added to every sample, including those under test, in order to evaluate the 
process control for each study as well as aiding in the data curation. 
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Supplemental Tables 
Table S1. Microarray matrix of gene expression in Acsl1flox/flox control and Acsl1H-/- knockdown 
(2-week) and knockout (10-week) hearts.  See Supplementary Excel file.  The 137 2-week 
centric genes identified via cluster analysis are listed, including the Agilent probe ID, p-values of 
genotype, treatment, and genotype and treatment intersection, absolute value of Log2 fold 
change, and the gene description.  
Table S2.  Complete table of differential gene expression in Acsl1H-/- knockdown hearts.  See 
Supplementary Excel file.  The 145 differentially expressed genes exhibiting a significant fold-
change ≥ 1.5 identified via 2-way ANOVA analysis are listed (“RNAseq, FC ≥ 1.5” tab), including 
the Entrez probe ID, absolute value of Log2 fold change, and the gene description. The directions 
of change, positive or negative in Acsl1H-/- hearts, are color coded yellow and blue, respectively. 
Cells in green indicate a p-value ≤ 0.01.  A third tab lists differentially expressed genes exhibiting 
a significant fold-change < 1.5 (“RNAseq, FC < 1.5” tab). 
Table S3.  Complete table of metabolites in Acsl1H-/- knockdown hearts.  See Supplementary 
Excel file.  Concentrations of metabolites identified by liquid or gas chromatography/mass 
spectrometry (LC/MS, LC/MS/MS, GC/MS) were log transformed, unit scaled, and normalized. 
The 64 metabolites altered in hearts exhibiting reduced ACSL1 activity identified by 2-way ANOVA 
are listed.  The directions of change, positive or negative in Acsl1H-/- hearts, are color coded yellow 
and blue, respectively.  Cells in green indicate a p-value ≤ 0.01. 
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Figure S1. Normalization of metabolite concentrations results in Gaussian distributions.  
Prior to statistical analysis, raw metabolite concentrations were analyzed using Metaboanalyst 
(v3.0) run in the statistical package R (v3.3.2) (1-3). Concentrations were log transformed and 
unit scaled.  The data distributions before and after normalization are provided both per metabolite 
(A) and per sample (B). These normalized data were used for PCA and 2-way ANOVA analyses
to identify metabolites that associated with genotype or rapamycin treatment (Fig. 7, Table S3). 
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Figure S2. Expression of mTORC1 components and autophagy genes confirms mTOR 
activation in Acsl1H-/- knockdown hearts.  A, Induction of mTORC1 inhibitor components 
Deptor and Rptor (4).  B,  Repression of various genes involved in autophagy in response to 
mTOR activation resulting from Acsl1H-/- knockdown.  n = 5 per group.  The values reported are 
means ± SEM (error bars).  *, p ≤ 0.05; **, p < 0.01 compared with littermate controls;  denotes 
genes whose altered expression in Acsl1H-/- knockdown hearts was reverted by rapamycin 
treatment. 
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Figure S3. The effect of RNA technology platform on relative expression levels. Seven of 
the 13 genes from Figure 6A were identified on both the array and RNAseq platforms. The relative 
expression of these genes from each platform were mean centered on each control condition 
(Array- Acsl1flox/flox or RNAseq- Acsl1flox/flox) and are represented on the bar graph as the mean ± 
SEM (N = 3 – 5 biological replicates per condition). Two-way ANOVA using genotype (Acsl1H-/- 
vs. Acsl1flox/flox) and platform (Array vs. RNAseq) as the factors identified that the genotype 
accounted for the variance seen across all seven genes (estimate range 0.4 – 0.9, †, ††, and ††† 
correspond to p < 0.05, 0.01, and 0.001, respectively). The expression difference in Ecm2 was 
also influenced by the platform (estimate 0.5, ** p = 0.0053) and the interaction between platform 
and genotype (estimate 0.4 ‡, p = 0.0060), which were about half of the estimate of the genotype 
effect (0.8, p < 0.0001). 
Pascual et al. Supplementary Material 10 
Supplemental References 
1. Xia J, Mandal R, Sinelnikov IV, Broadhurst D, Wishart DS. MetaboAnalyst 2.0--a
comprehensive server for metabolomic data analysis. Nucleic Acids Res. 2012;40:W127-
133.
2. Xia J, Psychogios N, Young N, Wishart DS. MetaboAnalyst: a web server for metabolomic
data analysis and interpretation. Nucleic Acids Res. 2009;37:W652-660.
3. Xia, J, Wishart DS. Web-based inference of biological patterns, functions and pathways
from metabolomic data using MetaboAnalyst. Nat. Protoc. 2011;6:743-760.
4. Kim, DH, Sarbassov DD, Ali SM, King, JE, Latek RR, Erdjument-Bromage H, Tempst P,
Sabatini DM. mTOR interacts with raptor to form a nutrient-sensitive complex that signals
to the cell growth machinery. Cell. 2002;110:163-175.
